Drugs Industry, Genentech | featured news

Genentech, Roche Deal Hits Snag

Deal talks between Genentech and Roche hit a snag over dueling interpretations of arcane SEC rules, but the problem is unlikely to derail the transaction, according to people familiar with the matter.

 

Roche Raises Bid for Genentech

Roche Raises Bid for Genentech

Swiss drug company Roche Holding increased its offer to acquire the rest of Genentech to $93 a share from $86.50.

 

Subscribe to this RSS topic: Syndicate content